MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$112,000

Operating Income

-$95M

Net Income

-$84M

EPS (Diluted)

$-4.73

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$442M

Total Liabilities

$25M

Stockholders' Equity

$417M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$112,000	-$96,000	-16.7%
Operating Income	-$95M	-$40M	-134.8%
Net Income	-$84M	-$33M	-155.9%

MDGL FY 2019 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena